Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus (vol 22, 185, 2023)

被引:0
|
作者
Lyu, Young Sang [1 ]
Oh, Seok [2 ]
Kim, Jin Hwa [1 ]
Kim, Sang Yong [1 ]
Jeong, Myung Ho [2 ,3 ]
机构
[1] Chosun Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Gwangju, South Korea
[2] Chonnam Natl Univ Hosp, Departmnent Cardiol, Gwangju, South Korea
[3] Chonnam Natl Univ, Med Sch, Dept Cardiol, Gwangju, South Korea
关键词
Antidiabetic agents; Diabetes mellitus; Hypoglycemic agents; Myocardial infarction;
D O I
10.1186/s12933-023-01960-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus, real-world evidence regarding their benefits to diabetic patients with acute myocardial infarction (AMI) is insufficient. This study evaluated cardiovascular outcomes by comparing SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4i) in combination with metformin in diabetic patients with AMI. Methods: This study involved 779 diabetic participants with AMI from a Korean nationwide multicenter observational cohort, who were divided into two groups: (1) metformin plus SGLT2i group (SGLT2i group, n = 186) and (2) metformin plus DPP-4i (DPP-4i group, n = 593). The primary endpoint was one year of major adverse composite events (MACEs), a composite outcome of all-cause mortality, non-fatal myocardial infarction, any revascularization, cerebrovascular accident, and stent thrombosis. To balance the baseline differences, inverse probability of treatment weighting (IPTW) was performed. Results: After IPTW, the rate of MACEs in the SGLT2i group was not significantly lower than that in the DPP-4i group (hazard ratio [HR], 0.99; 95% confidence interval [Cl], 0.46 to 2.14, p = 0.983). In the unadjusted and adjusted analyses, all items for clinical outcomes were comparable between the two groups. In our exploratory analysis, the left ventricular ejection fraction showed a significant improvement in the SGLT2i group than in the DPP-4i group before achieving statistical balancing (6.10 ± 8.30 versus 2.95 ± 10.34, p = 0.007) and after IPTW adjustment (6.91 ± 8.91 versus 3.13 ± 10.41, p = 0.027). Conclusions: Our findings demonstrated that SGLT2i did not influence the rate of MACEs compared with DPP-4i in combination with metformin in diabetic patients with AMI but did improve left ventricular ejection fraction. Trial registration: Not applicable (retrospectively registered). © 2023, The Author(s).
引用
收藏
页数:1
相关论文
共 50 条
  • [41] SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART
    Rosen, Hans Christian
    Mohammad, Moman A.
    Jernberg, Tomas
    James, Stefan
    Oldgren, Jonas
    Erlinge, David
    LANCET REGIONAL HEALTH-EUROPE, 2024, 45
  • [42] Characteristics of patients with diabetes and a history of myocardial infarction initiating PCSK9 and SGLT2 inhibitors
    Hubbard, Demetria
    Mckinley, Emily C.
    Colantonio, Lisandro D.
    Poudel, Bharat
    Rosenson, Robert S.
    Brown, Todd M.
    Jackson, Elizabeth A.
    Huang, Lei
    Orroth, Kate K.
    Mues, Katherine E.
    Dluzniewski, Paul J.
    Bittner, Vera
    Muntner, Paul
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2022, 13
  • [43] SGLT2 INHIBITORS AND KIDNEYS: MECHANISMS AND MAIN EFFECTS IN DIABETES MELLITUS PATIENTS
    Salukhov, Vladimir V.
    Khalimov, Yurii Sh
    Shustov, Sergey B.
    Popov, Sergey, I
    DIABETES MELLITUS, 2020, 23 (05): : 475 - 491
  • [44] Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
    Ribola, F. A.
    Cancado, F. B.
    Schoueri, J. H. M.
    De Toni, V. F.
    Medeiros, V. H. R.
    Feder, D.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (01) : 199 - 211
  • [45] The effect of SGLT2 inhibitors on drugnaive obese type 2 diabetes mellitus patients
    Chikazawa, Shinji
    Matsuhashi, Yuki
    Tando, Yusuke
    Daimon, Makoto
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S103 - S103
  • [46] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [47] Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
    Cho, Y. K.
    Kang, Y. M.
    Lee, S. E.
    Lee, J.
    Park, J. -Y.
    Lee, W. J.
    Kim, Y. -J.
    Jung, C. H.
    DIABETES & METABOLISM, 2018, 44 (05) : 393 - 401
  • [48] Positive effects of SGLT2 inhibitors on cardiac markers after acute myocardial infarction are similar in patients with and without type 2 diabetes
    Aziz, Faisal
    Oulhaj, Abderrahim
    Tripolt, Norbert
    Pferschy, Peter
    von-Lewinski, Dirk
    Sourij, Harald
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S752 - S753
  • [49] In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
    Liakos, Aris
    Tsapas, Apostolos
    Bekiari, Eleni
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (12) : JC70 - JC70
  • [50] Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients
    Cao, Yang
    Liang, Ning
    Liu, Ting
    Fang, Jingai
    Zhang, Xiaodong
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2023, 23 (04) : 530 - 547